Analysis of Phytochemicals from Camptotheca acuminata, Curcuma longa, and Diphylleia grayi Against a Complex of ERK2 with Catechol

Cancer remains a daunting global health challenge that requires continuous efforts to understand its underlying mechanisms and develop novel therapeutic strategies. This comprehensive research focuses on recent advances in cancer research, focusing on emerging therapies and the challenges encountered in the fight against this complex disease. This work used different phytochemicals obtained from Camptotheca acuminata, Curcuma longa, and Diphylleia grayi to verify the Complex of ERK2 with Catechol (PDB - 4ZXT), a receptor for lung cancer. The complex of ERK2 with Catechol was used to study the binding interactions through the molecular docking model. This study has found that most of the compounds have the potential to inhibit the disorder. Compounds, especially 10-hydroxycamptothecin from Camptotheca acuminata, Cyclocurcumin from Curcuma longa, and Diphyllin from Diphylleia grayi, have the minor binding energies of -7.62 kcal/mol, -7.41 kcal/mol, and -7.99 kcal/mol, respectively, which can inhibit the receptor. This study will provide insights into possible treatments for lung cancer during interactions between various phytochemicals and cancer receptors. We can take the compounds to in vitro studies to find a more effective compound.